Protara Therapeutics (TARA) - Uzoq muddatli qarzning kapitalga nisbati
Jesse Shem tomonidan qo'llab-quvvatlanadigan Protara Therapeutics (TARA) kompaniyasining joriy aksiya narxi grafigi kapitalning ishonchli nazorati va klinika rivojlanishini namoyish etadi, bunda ko'rsatkich 0.01 ga yetadi. Protara Therapeutics ilmiy markazlar bilan hamkorlik orqali dori vositalarini chiqarilishini tezlashtirmoqda. Biznes noyob o'smalar bilan kasallangan bemorlar uchun maqsadli dori vositalarini yaratishga tayanadi va davlat sug'urta fondlaridan kelajakdagi to'lovlarni kutadi.
%20Uzoq%20muddatli%20qarzning%20o'z%20kapitaliga%20nisbati&width=1200&height=400&colorIndex=0&v=mvt4kixj.9g-7avve2o&start=20220704&end=20261029&filename=GURU_Markets_-_TARA_-_Protara-Therapeutics_-_Long-Term-Debt-to-Equity "protaratx.com (TARA): Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi 04.07.2022dan 29.10.2026gacha | 👁️GURU.Markets👁️")
Protara Therapeutics kompaniyasining tahliliy kesimlari
- aksiyalar qiymati va narxlar bo'yicha konsensus prognoz:
- bozor kapitallashuvi ko'rsatkichlari:
- kompaniyaning balans qiymati tafsilotlari:
- kompaniyaning majburiyatlari va likvidligi ma'lumotlari:
Qarzning kapitalga nisbati Protara Therapeutics|TARA - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzdorlikning kapitalga nisbati protaratx.com|TARA - Kompaniyaning umumiy qarzi|Qarzning sof aktivlarga nisbati Protara Therapeutics, Inc.|TARA - Kompaniyaning uzoq muddatli qarzlari|Kompaniyaning qisqa muddatli majburiyatlari Protara Therapeutics|Tezkor likvidlik koeffitsiyenti protaratx.com
- moliyaviy natijalar va qiymat multiplikatorlari tafsilotlari:
Kompaniyaning umumiy tahlili:Protara Therapeutics Inc - TARA
Ushbu ko'rsatkich uzoq muddatli majburiyatlarning kapitalga nisbatini aniqlaydi, bu esa moliyaviy avtonomiyani va bir yildan ortiq muddatga ega bo'lgan kreditlarni xizmat ko'rsatish bilan bog'liq xatarlarni baholash imkonini beradi. Uzoq muddatli qarzlarning kapitalga nisbatini tahlil qilish orqali investor Protara Therapeutics (TARA) kompaniyasi aniq onkologiya va hujayra terapiyasi sohasidagi kapital talab qiluvchi R&D platformalarini moliyalashtirishda tashqi qarz mablag'lariga qanchalik tayanishini tushunishi mumkin.
Muhim raqobatchilar
Uzoq muddatli qarzning o'z kapitaliga nisbati BeiGene Ltd. (ONC)|Uzoq muddatli qarzning kapitalga nisbati HALO|Uzoq muddatli qarzning kapitalga nisbati Revolution Medicines Corp (RVMD)|Uzoq muddatli qarzning o'z kapitaliga nisbati Ascentage Pharma Group AAPG|CGON: Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi|UroGen Pharma - Uzoq muddatli qarzning kapitalga nisbati|Bicara Therapeutics Inc (BCAX) - Uzoq muddatli qarzning o'z kapitaliga nisbati|PSNL: Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati Erasca Oncology (ERAS)|Uzoq muddatli qarzning o'z kapitaliga nisbati Delcath Systems, Inc.|YMAB: Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning o'z kapitaliga nisbati AURA (Aura Biosciences)|CADL (candeltx.com) - Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning kapitalga nisbati ARAY (Accuray Inc.)|SLS - Uzoq muddatli qarzning o'z kapitaliga nisbati|ACTU: Uzoq muddatli qarzning o'z kapitaliga nisbati|CTOR - Uzoq muddatli qarzning kapitalga nisbati|tuhurabio.com (HURA) - Uzoq muddatli qarzning o'z kapitaliga nisbati|Fate Therapeutics Inc - Uzoq muddatli qarzning kapitalga koeffitsiyenti|WHWK (Aadi Bioscience, Inc.) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati TScan TCRX|Uzoq muddatli qarzning o'z kapitaliga nisbati Champions Oncology (CSBR)|XBIT: Uzoq muddatli majburiyatlarning o'z kapitaliga nisbati|Uzoq muddatli qarzning o'z kapitaliga nisbati CEL-SCI CVM|Uzoq muddatli qarzning kapitalga koeffitsiyenti OSTX|RADX - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati Artiva Biotherapeutics, Inc.|ANL (adlainortye.com) - Uzoq muddatli qarzning o'z kapitaliga nisbati|VERU: Uzoq muddatli kreditlarning kapitalga nisbati|TPST (Tempest Therapeutics, Inc.) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzning kapitalga nisbati Xilio|Uzoq muddatli qarzning o'z kapitaliga nisbati Renovaro Inc. (RENB)|MURA (muraloncology.com) - Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning kapitalga nisbati KAPA (Kairos Pharma)|Uzoq muddatli qarzning kapitalga nisbati OnKure Therapeutics, Inc. OKUR|GDTC: Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli qarzning kapitalga koeffitsiyenti CRIS (Curis, Inc.)|APLM (apollomicsinc.com) - Uzoq muddatli qarzning o'z kapitaliga nisbati|THAR: Uzoq muddatli kreditlarning kapitalga nisbati|ADVB (Advanced Biomed Inc.) - Uzoq muddatli qarzning kapitalga nisbati|GNPX: Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning kapitalga nisbati CLDI|SBFM - Uzoq muddatli majburiyatlarning kapitalga nisbati|Uzoq muddatli qarzning o'z kapitaliga nisbati Xenetic Biosciences, Inc. XBIO|Uzoq muddatli qarzning kapitalga koeffitsiyenti SLRX|Purple Biotech - Uzoq muddatli qarzning kapitalga nisbati|AONC - Uzoq muddatli qarzning kapitalga nisbati|BeiGene (BGNE) - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli majburiyatlarning o'z kapitaliga nisbati CKPT (Checkpoint Therapeutics Inc.)|ELEV (Elevation Oncology, Inc.) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati iCAD Corp ICAD|Uzoq muddatli qarzning o'z kapitaliga nisbati IKNA (Ikena Oncology, Inc.)|Uzoq muddatli qarzning kapitalga nisbati notablelabs.com (NTBL)|Viracta Therapeutics, Inc. - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli kreditlarning kapitalga nisbati MOR (MorphoSys Inc)|NAYA Bio - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzdorlikning kapitalga nisbati Ascentage AAPGV